Skip to main
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics is a promising biopharmaceutical company with a strong focus on developing and commercializing their main therapeutic candidate, ONS-5010, for the treatment of wet age-related macular degeneration (wAMD). Despite facing some challenges with FDA approvals, the company has demonstrated promising clinical progress and a potential for significant revenue growth in the future. With multiple positive developments in their pipeline, there is a high possibility for a successful launch and significant upside potential for the company's stock.

Bears say

Outlook Therapeutics is facing multiple challenges in the near future, with the FDA issuing a third Complete Response Letter for their resubmitted BLA for ONS-5010. Additionally, while their current European launch of LYTENAVA has been successful, they face potential pricing and reimbursement obstacles in the U.S market. Furthermore, the use of compounded bevacizumab could decrease if LYTENAVA is approved, presenting a threat to OTLK's potential market share.

OTLK has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 3 analysts, OTLK has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.